Immunosuppression

• Sumitomo Pharma Switzerland

  Company1 trialPhase 12 people

• Albert Einstein Healthcare Network

  1 trialPhase 2/335 people

• National Institute of Allergy and Infectious Diseases

  2 trialsPhase 2805 people

• Memorial Sloan Kettering Cancer Center

  1 trialPhase 245 people

• Azienda Ospedaliera San Giovanni Battista

  1 trialPhase 242 people

• Fred Hutchinson Cancer Center

  1 trialPhase 221 people

• University of Nebraska

  1 trialPhase 220 people

• Prof. Dr. med. Wolfgang Bethge

  1 trialPhase 29 people

National Institute of Allergy and Infectious DiseasesUS$3mNational Institute of Diabetes and Digestive and Kidney DiseasesUS$2.1mNational Cancer InstituteUS$848.5k

• Generating Exogenic Organs for Transplantation without the Use of Immunosuppression

  National Institute of Allergy and Infectious DiseasesUniversity of MinnesotaUS$731.3k2022–2027

• Preventing UV-induced immunosuppression and skin carcinogenesis with R-carvedilol

  National Cancer InstituteWestern University of Health SciencesUS$322.5k2022–2027

• The role of immunosuppression and environmental exposures on incident and subsequent keratinocyte carcinoma risk after solid organ transplant

  National Cancer InstituteUniversity of PennsylvaniaUS$526k2025–2030

• Vascularized Islet transplantation NICHE with local immunosuppression for the treatment of type 1 diabetes

  National Institute of Diabetes and Digestive and Kidney DiseasesThe Methodist Hospital Research InstituteUS$697.2k2022–2027

• Elucidation of the relationship between the effects of perioperative immunosuppression on neural activity and postoperative cognitive impairment

  Japan Society for the Promotion of ScienceChiba UniversityJP¥4.2m2022–2025